BAILLIE GIFFORD & CO 13D and 13G filings for Alnylam Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-07-05 10:24 am Sale | 2024-06-28 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | BAILLIE GIFFORD & CO | 6,032,656 4.770% | -934,441 (-13.41%) | Filing |
| 2024-01-29 12:18 pm Sale | 2023-12-29 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | BAILLIE GIFFORD & CO | 6,967,097 5.550% | -2,440,774 (-25.94%) | Filing |
| 2023-01-19 12:08 pm Sale | 2022-12-30 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | BAILLIE GIFFORD & CO | 9,407,871 7.650% | -1,208,880 (-11.39%) | Filing |
| 2022-01-18 07:06 am Purchase | 2021-12-31 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | BAILLIE GIFFORD & CO | 10,616,751 8.880% | 1,484,329 (+16.25%) | Filing |
| 2021-02-01 10:12 am Purchase | 2020-12-31 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | BAILLIE GIFFORD & CO | 9,132,422 7.860% | 945,699 (+11.55%) | Filing |